Roche Investor Relations ASCO Planner 2017

Transcription

1 Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi, MD, PhD; Stephen V. Liu, MD Abstract 9025 Genomic profiling of circulating tumor DNA (ctdna) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Board #351 Abstract 9064 Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Poster Board #390 Abstract 9092 Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. Poster Board #418 Session Title: Gynecologic Cancer Date: Sat, June 3 Time: 1:15 PM 4:45 PM Speaker Name: Gini F. Fleming, MD, FASCO Abstract 5585 Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rec). Poster Board #407 F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations investor.relations@roche.com Tel Fax

2 Sunday, June 4 Session Title: Breast Cancer Metastatic Session Type: Poster Discussion Session Speaker Name: Rebecca Alexandra Dent, MD Abstract 1009 LOTUS (NCT ): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC). Poster Board #1 Additionally discussed at the Poster Discussion Session on Sunday, June 4, 2017, 4:45 PM - 6:00 PM, at Hall B1 Session Title: Pediatric Oncology Speaker Name: Birgit Geoerger, MD Abstract A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (imatrix-atezolizumab). Poster Board #281 Additionally discussed at the Poster Discussion Session on Sunday, June 4, 2017, AM AM, at S504 Session Title: "Check" This Out: The Step Beyond PD-1 Blockade Session Type: Clinical Science Symposium Time: 9:45 AM - 11:15 AM Speaker Name: Howard A. Burris, MD, FASCO 10:24 AM - 10:36 AM Abstract 105 A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. 2/5

3 Session Title: Plenary Session Including the Science of Oncology Award and Lecture Session Type: Plenary Session Location: Hall B1 Time: 1:00 PM - 4:00 PM Chair and/or Co-Chairs: David C. Smith, MD, FACP, University of Michigan; Daniel F. Hayes, MD, FASCO, University of Michigan Comprehensive Cancer Center Monday, June 5 Session Title: Genitourinary (Nonprostate) Cancer Location: Arie Crown Theater Time: 8:00 AM - 11:00 AM Speaker Name: Michael B. Atkins, MD 9:24 AM 9:36 AM Abstract 4505 IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mrcc) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Session Title: Developmental Therapeutics Clinical Pharmacology and Experimental Therapeutics Speaker Name: Ignacio Melero, MD, Full Prof Abstract 2549 Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. Poster Board #41 Session Title: Developmental Therapeutics Immunotherapy Speaker Name: Wilson H. Miller, MD, PhD; Ryan J. Sullivan, M.D. Abstract 3057 Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. Poster Board #152 3/5

4 Abstract 3063 Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. Poster Board #158 Session Title: Breast Cancer Local/Regional/Adjuvant Location: Hall D2 Time: 9:45 AM - 12:45 PM Speaker Name: Gunter Von Minckwitz, MD, PhD 9:45 PM - 9:57 AM Abstract LBA500 APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). Session Title: Developmental Therapeutics Immunotherapy Time: 1:15 PM - 4:15 PM Speaker Name: Josep Tabernero, MD, PhD 1:39 PM 1:51 PM Abstract 3002 Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mcrc). Session Title: Health Services Research, Clinical Informatics, and Quality of Care Time: 1:15 PM - 4:45 PM Speaker Name: James Signorovitch, PhD Abstract 6599 Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. health plan population. Poster Board #421 4/5

5 Tuesday, June 6 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Tue, June 6 Time: 9:45 AM - 12:45 PM Speaker Name: David R. Gandara, MD, FASCO; Jaafar Bennouna, MD; Alice Tsang Shaw, MD, PhD 9:57 AM 10:09 AM Abstract 9001 Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. 10:57 AM 10:09 AM Abstract 9004 Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo). 12:09 PM 12:21 PM Abstract LBA9008 Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. 5/5